Last $22.15 USD
Change Today -0.415 / -1.84%
Volume 2.9K
GLAXF On Other Exchanges
New York
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GLAXF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $28.56
52 Week Low
12/16/14 - $20.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

glaxosmithkline plc (GLAXF) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc (GLAXF) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc (GLAXF) Key Developments

European Commission Approves Both GSK's Acquisition of Novartis' Vaccines Business and Consumer Healthcare Joint Venture Between GSK and Novartis

The European Commission has cleared under the EU Merger Regulation both the proposed acquisition of the vaccines business of Novartis' by GlaxoSmithKline, as well as the proposed creation of a new entity combining the consumer health activities of GSK and Novartis. The decision is conditional upon the divestiture of assets in the vaccines and consumer health businesses. The Commission had concerns that the transaction would have eliminated an important competitor to GSK for the supply of several vaccines and consumer health products, which might lead to price increases for European consumers. The commitments address these concerns. As a result of the transaction: GSK will acquire Novartis' global human vaccines business, except the influenza vaccines business; and GSK and Novartis will combine their global consumer health business in a new entity, which will be controlled by GSK. This transaction is part of a 3-part inter-conditional deal between the two companies: in a separately notified case (M.7275) Novartis plans to acquire part of GSK's oncology business portfolio. In a separate decision taken, the Commission has also approved that part of the deal.

GlaxoSmithKline plc Announces Board Committee Changes

GSK announced that Sir Philip Hampton has been appointed as Chairman of the Nominations Committee with effect from Jan. 27, 2015, replacing Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board. In addition, Ms. Lynn Elsenhans has also been appointed a member of the Committee, effective Jan. 27, 2015.

GlaxoSmithKline plc Expands its Portfolio of Medicines in the US for Patients with Asthma and COPD

GlaxoSmithKline plc announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in the US, all delivered in its Ellipta inhaler. Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma. It is the first product in the Ellipta inhaler for the treatment of asthma to be introduced in the US. Arnuity Ellipta is indicated for once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity Ellipta is not indicated for the relief of acute bronchospasm. It acts to reduce inflammation associated with asthma and helps to prevent and control the symptoms of asthma. Arnuity Ellipta is available in two approved doses, 100mcg and 200mcg. GSK also announced that Incruse Ellipta (umeclidinium bromide), an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, is now available to retail pharmacies in the US. Incruse is GSK's first anticholinergic monotherapy, a type of bronchodilator that can relax airway smooth muscles and improve airflow in and out of the lungs. Incruse Ellipta is available as 62.5mcg of umeclidinium dry inhalation powder, administered once-daily using the Ellipta inhaler.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLAXF:US $22.15 USD -0.415

GLAXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $162.30 USD -3.83
AbbVie Inc $60.35 USD -2.77
Amgen Inc $152.26 USD -4.11
Bristol-Myers Squibb Co $60.27 USD -0.87
Sanofi €82.00 EUR -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation GLAXF Industry Range
Price/Earnings 15.9x
Price/Sales 2.8x
Price/Book 13.0x
Price/Cash Flow 15.8x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at